Clinical Trials Logo

Cirrhosis clinical trials

View clinical trials related to Cirrhosis.

Filter by:

NCT ID: NCT06052150 Recruiting - Cirrhosis Clinical Trials

Oral Health In Cirrhosis of the Liver (ORACLE)

ORACLE
Start date: September 18, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about dental evaluation and periodontal cleaning along with scheduled follow -up on the dental health and overall health of patients with cirrhosis and also to determine what barrier(s) if any exist to improve oral health in this population.

NCT ID: NCT06007846 Recruiting - Clinical trials for Hepatocellular Carcinoma

A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer

Start date: July 31, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This is a single-site prospective study to describe efficacy endpoints of single agent memantine in patients with unresectable, locally advanced, or metastatic HCC otherwise not deemed candidates for intensive systemic therapy. In addition to the primary endpoint and multiple secondary efficacy endpoints, we will describe changes in quality of life on treatment over time.

NCT ID: NCT06000748 Recruiting - Acute Kidney Injury Clinical Trials

NEPH-ROSIS (NEPHrology in CirRhOSIS) Pilot Trial: A Trial to Treat Acute Kidney Injury Among Hospitalized Cirrhosis Patients

NEPH-ROSIS
Start date: February 1, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this pilot, randomized, single-blind clinical trial is to estimate the effect size of a high and low mean arterial pressure (MAP)-target algorithm among cirrhosis patients hospitalized with acute kidney injury. The main aims to answer are: • Does an algorithm that has low (<80 mmHg) and high (≥80) MAP-targets lead to significant differences in mean arterial pressure? • Are there any serious adverse events (e.g., ischemia) in a high blood pressure algorithm as compared to a low blood pressure algorithm? • Are there any differences in the incidence of AKI reversal in the high v. low MAP-target groups? Participants will be: 1) Randomized to a clinical algorithm that will either target a low (<80 mmHg) or high (≥80 mmHg) MAP. 2) Depending on their group, investigators will titrate commonly used medications to a specific MAP target. Researchers will compare the high and low MAP-target groups to see if these algorithms lead to significant changes in MAP, if they have any impact on AKI reversal, and if there are any adverse events in the high MAP-target group.

NCT ID: NCT05998330 Recruiting - Cirrhosis Clinical Trials

LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease

LiverPAL
Start date: September 20, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate whether early integration of palliative care in the care of hospitalized patients with advanced liver disease (AdvLD) can improve patients' quality of life, physical symptoms, mood, and serious illness communication. Palliative care is a medical specialty focused on lessening (or "palliating") symptoms and assisting in coping with serious illness.

NCT ID: NCT05832229 Recruiting - Cirrhosis Clinical Trials

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

LCN RESCU
Start date: October 11, 2023
Phase: Phase 2
Study type: Interventional

This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.

NCT ID: NCT05797649 Recruiting - Heart Failure Clinical Trials

Comparing N-terminal-proB-type Natriuretic Peptide With Other Criteria in Pleural Fluid Analysis

Start date: July 1, 2023
Phase:
Study type: Observational [Patient Registry]

To assess the discriminative properties of pleural fluid (PF) N-terminal-proB-type-natriuretic-peptide (NTproBNP) levels in identifying heart failure (HF)-associated pleural effusions (PE).

NCT ID: NCT05782283 Recruiting - Cirrhosis Clinical Trials

A Study to Detect Advanced Liver Disease Via AI-enabled Electrocardiogram

ADVANCE
Start date: April 18, 2023
Phase: N/A
Study type: Interventional

The overall objectives of this study are to determine the effectiveness of ACE 2.0 model in early detection of advanced liver fibrosis, and to determine the acceptance and barriers for use of an AI-enabled algorithm for prediction of liver disease in primary care.

NCT ID: NCT05769868 Recruiting - Diabetes Mellitus Clinical Trials

Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments

CIBERbBECHO
Start date: April 18, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the superiority of esmolol echocardiography over conventional echocardiography in the diagnosis of subclinical myocardial involvement associated with diabetes mellitus 2, cirrhosis and antineoplastic treatments.

NCT ID: NCT05740358 Recruiting - Cirrhosis Clinical Trials

Liver Cirrhosis Network Cohort Study

LCN-C
Start date: November 14, 2022
Phase:
Study type: Observational

Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis. LCN Cohort Study involves multiple institutions and an anticipated 1200 participants. Enrolled participants will have study visits every 6 months (180 days), with opportunities to complete specific visit components via telehealth or remotely. Visits will include collection of questionnaire data and the in-person visits will include questionnaires, physical exams, imaging, and sample collection.

NCT ID: NCT05737030 Recruiting - Cirrhosis Clinical Trials

Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome

LOLAbiome
Start date: February 6, 2023
Phase: Phase 4
Study type: Interventional

Study to test the effect of the drug "L-ornithine.L-aspertate" (LOLA) on microorganisms in the digestive tract in patients with liver cirrhosis (damage of the liver due to liver disease)